Cerebrovascular Events in Glioma Patients Treated with Bevacizumab

被引：0
|
作者：
Patel, Donika K. [1 ]
John, Seby [1 ]
Hashemi-Sadraei, Neda [1 ]
Ahluwalia, Manmeet [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
STROKE | 2013年 / 44卷 / 02期
关键词：
Cerebrovascular disorders; Cerebrovascular circulation;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cerebrovascular Events in Glioma Patients Treated with Bevacizumab
    Patel, Donika
    John, Seby
    Hashemi-Sadraei, Neda
    Ahluwalia, Manmeet
    [J]. NEUROLOGY, 2013, 80
  • [2] Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis
    Zuo, Pei-Yuan
    Chen, Xing-Lin
    Liu, Yu-Wei
    Xiao, Chang-Liang
    Liu, Cheng-Yun
    [J]. PLOS ONE, 2014, 9 (07):
  • [3] SURVIVAL OUTCOMES OF PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA TREATED WITH BEVACIZUMAB
    Hamza, Mohamed
    O'Brien, Barbara
    Mandel, Jacob
    DeGroot, John
    [J]. NEURO-ONCOLOGY, 2013, 15 : 110 - 111
  • [4] Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan
    Toft, Anders
    Urup, Thomas
    Christensen, Ib Jarle
    Michaelsen, Signe Regner
    Lukram, Babloo
    Grunnet, Kirsten
    Kosteljanetz, Michael
    Larsen, Vibeke Andree
    Lassen, Ulrik
    Broholm, Helle
    Poulsen, Hans Skovgaard
    [J]. CANCER INVESTIGATION, 2018, 36 (02) : 165 - 174
  • [5] THE PROGNOSTIC VALUE OF FET PET IN PATIENTS WITH RECURRENT GLIOMA TREATED WITH BEVACIZUMAB
    Werner, Jan-Michael
    Winkels, Myriam
    Lohmann, Philipp
    Ceccon, Garry
    Wollring, Michael
    Tscherpel, Caroline
    Bauer, Elena
    Goldbrunner, Roland
    Stoffels, Gabriele
    Langen, Karl-Josef
    Fink, Gereon R.
    Galldiks, Norbert
    [J]. NEURO-ONCOLOGY, 2022, 24 : 168 - 168
  • [6] Risk of Cerebrovascular Events in Migraine Patients Treated with Prophylactic Medications
    Hoffman, V
    Xue, F.
    Green, E.
    Eisele, O.
    Kurth, T.
    Seeger, J.
    [J]. HEADACHE, 2017, 57 : 173 - 174
  • [7] THE RISK AND BURDEN OF THROMBOEMBOLIC AND HEMORRHAGIC EVENTS IN PATIENTS WITH MALIGNANT GLIOMA RECEIVING BEVACIZUMAB
    Ou, Alexander
    Lin, Heather
    Yuan, Ying
    Bornstein, Charles
    Alfaro-Munoz, Kristin
    Afshar-Kharghan, Vahid
    Kamiya-Matsuoka, Carlos
    Majd, Nazanin
    [J]. NEURO-ONCOLOGY, 2021, 23 : 148 - 148
  • [8] Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis
    Dong, Jiawei
    Meng, Xiangqi
    Li, Siyi
    Chen, Qun
    Shi, Lei
    Jiang, Chuanlu
    Cai, Jinquan
    [J]. WORLD NEUROSURGERY, 2019, 130 : E236 - E243
  • [9] OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (HGG) TREATED WITH BEVACIZUMAB
    Ye, L.
    Hasani, A.
    Nowak, A.
    King, A.
    Long, A.
    Trevenen, M.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 72 - 72
  • [10] Thromboembolic events and bleeding in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
    Isabel Ferrer, Ana
    Luis Sanchez, Jose
    Carmen Rodriguez, Maria
    Soriano, Carmen
    Alberto Aliaga, Luis
    Garcia Nieto, Sandra
    Carmen Alonso, Maria
    Fernandez, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345